Literature DB >> 18752867

Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.

Ri Cui1, Fumiyuki Takahashi, Rina Ohashi, Masakata Yoshioka, Tao Gu, Ken Tajima, Takeshi Unnoura, Shinichiro Iwakami, Michihiro Hirama, Toshiji Ishiwata, Akihiko Iwase, Kazuhisa Takahashi.   

Abstract

Malignant pleural effusion (MPE) is associated with advanced-stage lung cancer and is a poor prognostic sign for these patients. Osteopontin (OPN) is a multifunctional cytokine that is involved in the tumor progression and angiogenesis of lung cancer cells. The purpose of this study is to investigate and provide evidence for the role of OPN in the formation of MPE associated with lung cancer. In this study, we established an OPN knockdown murine lung cancer cell line, 3LL cells, utilizing the small interfering RNA (siRNA) technique. To reveal the effect of OPN on the formation of MPE associated with lung cancer, we directly injected OPN knockdown 3LL cells, 3LL/OPN siRNA, or control cells, 3LL/control siRNA, into the pleural space of C57BL/6 mice. OPN knockdown significantly reduced the formation of MPE, but did not inhibit in vivo tumor growth of 3LL cells in mice. Vascular endothelial growth factor (VEGF) concentration in MPE was markedly decreased in the 3LL/OPN siRNA in comparison with that of the 3LL/control siRNA. In vitro, recombinant OPN protein enhanced VEGF secretion from human umbilical vein endothelial cell (HUVEC) or human mesothelial cell line, Met5A cells, in a concentration-dependent manner. These results suggest that OPN is positively involved in the formation of MPE of lung cancer presumably by promoting VEGF secretion from vascular endothelial cells or mesothelial cells. OPN could be an effective target molecule for reducing MPE in lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752867     DOI: 10.1016/j.lungcan.2008.06.020

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Establishment of a malignant pleural effusion mouse model: pathogenesis pathways.

Authors:  Kalliopi Domvri; Paul Zarogoulidis; Fotis Theodoropoulos; Haidong Huang; Konstantinos Zarogoulidis
Journal:  Transl Lung Cancer Res       Date:  2012-09

3.  The role of α9β1 integrin and its ligands in the development of autoimmune diseases.

Authors:  Shigeyuki Kon; Toshimitsu Uede
Journal:  J Cell Commun Signal       Date:  2017-10-03       Impact factor: 5.782

Review 4.  Malignant pleural effusion: tumor-host interactions unleashed.

Authors:  Georgios T Stathopoulos; Ioannis Kalomenidis
Journal:  Am J Respir Crit Care Med       Date:  2012-05-31       Impact factor: 21.405

5.  Increased osteopontin-positive macrophage expression in colorectal cancer stroma with synchronous liver metastasis.

Authors:  Motohiro Imano; Kiyokata Okuno; Tatsuki Itoh; Eizaburo Ishimaru; Takao Satou; Hitoshi Shiozaki
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

6.  Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin.

Authors:  Massimo Dal Monte; Davide Martini; Chiara Ristori; Danilo Azara; Chiara Armani; Alberto Balbarini; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-04-28       Impact factor: 3.000

Review 7.  Aryl hydrocarbon receptor and lung cancer.

Authors:  Junchieh J Tsay; Kam-Meng Tchou-Wong; Alissa K Greenberg; Harvey Pass; William N Rom
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

Review 8.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

9.  MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.

Authors:  Wei Meng; Zhenqing Ye; Ri Cui; James Perry; Vaia Dedousi-Huebner; Alexander Huebner; Yao Wang; Bin Li; Stefano Volinia; Hiroshi Nakanishi; Taewan Kim; Sung-Suk Suh; Leona W Ayers; Patrick Ross; Carlo M Croce; Arnab Chakravarti; Victor X Jin; Tim Lautenschlaeger
Journal:  Clin Cancer Res       Date:  2013-08-14       Impact factor: 12.531

10.  Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.

Authors:  Li-Han Hsu; Ko-Jiunn Liu; Ming-Fang Tsai; Chang-Ru Wu; An-Chen Feng; Nei-Min Chu; Shu-Huei Kao
Journal:  Cancer Sci       Date:  2014-11-28       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.